Q2 2026 Evolus Inc Earnings Call Transcript
Key Points
- Evolus Inc (EOLS) delivered 21% revenue growth in Q2 2026, marking a significant inflection point and its third consecutive quarter of positive adjusted EBITDA.
- The company gained significant market share in the U.S. injectable aesthetics market, with global toxin revenue exceeding $75 million, driven by double-digit growth in both the U.S. and international markets.
- The launch of the Evolus portfolio growth bundle has been highly successful, with approximately 70% of participating customers purchasing Evolus products, compared to only 25% penetration across the overall customer base.
- Evolus Inc (EOLS) announced a strategic partnership with Ipsa to exclusively develop and commercialize Profhilo in the U.S., expanding into the new skin quality vertical with a product that has the potential to generate over $100 million in peak annual revenue.
- The company raised its full-year 2026 revenue guidance to a midpoint of $333.5 million and its adjusted gross profit margin guidance to 67.0%-67.5%, reflecting strong first-half performance and confidence in the business trajectory.
- Evolus Inc (EOLS) expanded its international footprint with the launch of Esteem in Europe and new licensing agreements for Canada, Australia, and New Zealand, expanding its global addressable market by approximately $200 million annually.
- Evolus Inc (EOLS) reported a GAAP gross margin of 68% for Q2 2026, which benefited from a one-time tariff refund of approximately 120 basis points, masking the underlying margin performance.
- Operating expenses increased sequentially in Q2 2026, with GAAP operating expenses rising to $61.7 million from $55.7 million in Q1, reflecting continued investment in customer education, marketing, and international expansion.
- The company's cash position decreased to $45.2 million at the end of Q2 2026 from $49.8 million at the end of Q1, primarily due to interest expense and planned capital expenditure investments.
- Evolus Inc (EOLS) faces ongoing tariff uncertainty, with the company prudently bringing approximately one year's worth of Jeuveau inventory into the U.S. to mitigate potential risks, which will increase inventory and accounts payable on the balance sheet.
- The Profhilo partnership is expected to require a full PMA process with an anticipated approval around 2030, representing a long development timeline before the product can contribute to revenue.
- The company's international business, while growing, still faces challenges in establishing market share, with the UK being the only market approaching double-digit share, indicating early-stage development in other European markets.
Good afternoon, everyone, and thank you for standing by. Welcome to Evolist's second quarter 2026 earnings call. If anyone should require operator assistance during the conference, please press *0 on your telephone keypad.
As a reminder, today's conference call is being recorded and webcast live. All participants are in the listen-only mode. After the speaker's remarks, there will be a question-and-answer session. I would now like to turn the conference over to Narek Saharian, Vice President and Head of Global Vestor Relations in Corporate Communications. Please go ahead.
Thank you, operator, and welcome to everyone joining us on today's call to review Evolus' second quarter financial results.
Our second quarter press release is now available on the Investor Relations section of our website at evolus.com.
Joining me on today's call are David Motozzetti, President and Chief Executive Officer Louis Avelar, Chief Medical Officer and Head of R&D and Tiana Mitchell, Chief Financial
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
